Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.55 |
| ▸ | NOS3 | P29474 | 5/20 | 0.55 |
| ▸ | NOS1 | P29475 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31500865 | 1.00 | NOS2 (0.55) | NOS2NOS3NOS1HRH3KDM4E | |
| SCHEMBL12309955 | 0.84 | NOS3 (0.43) | NOS2NOS3HRH3KMT2AMAPT | |
| SCHEMBL4435970 | 0.83 | NOS2 (0.61) | NOS2NOS3NOS1HRH3KMT2A | |
| SCHEMBL28303960 | 0.78 | NOS2 (0.55) | NOS2NOS3NOS1HRH3MAPT | |
| SCHEMBL1762646 | 0.77 | NOS3 (0.39) | NOS2NOS3HRH3KDM4EKMT2A | |
| SCHEMBL6361284 | 0.77 | NOS2 (0.59) | NOS2NOS3NOS1HRH3CDK2 | |
| SCHEMBL7015805 | 0.77 | NOS2 (0.38) | NOS2NOS3NOS1 | |
| SCHEMBL2719526 | 0.76 | NOS2 (0.57) | NOS2NOS3NOS1HRH3MAPT | |
| SCHEMBL12843993 | 0.76 | NOS2 (0.63) | NOS2NOS3NOS1HRH3 | |
| SCHEMBL2632759 | 0.76 | KMT2A (0.47) | NOS2NOS3KDM4EKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098029-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12509442-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12441705-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3898616-B1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240317715-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-12054476-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-11739072-B2 | Heteroaryl compounds and their use | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-29 | — | — | US | disclosed |
| US-20220106293-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220056015-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11236069-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3897852-A1 | KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3898616-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | Amgen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113226473-A | KIF18A inhibitors | 美国安进公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20200239441-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2020132648-A1 | KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020132649-A1 | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | AMGEN INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509442-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIFC1 | NOS2 4797/4885NOS3 4479/4885NOS1 4464/4885 |
| US-20240317715-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | NOS2 4315/4885NOS3 4245/4885NOS1 3907/4885 |
| US-12441705-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | NOS2 4275/4885NOS3 4061/4885NOS1 3902/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | NOS2 3084/4885NOS3 931/4885NOS1 2561/4885 |
| US-20220106293-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | NOS2 4315/4885NOS3 4245/4885NOS1 3907/4885 |
| US-20200239441-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | NOS2 4315/4885NOS3 4245/4885NOS1 3907/4885 |
| US-12054476-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | NOS2 4315/4885NOS3 4245/4885NOS1 3907/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | NOS2 3566/4885NOS3 2328/4885NOS1 4084/4885 |
| US-11739072-B2 | Heteroaryl compounds and their use | GBA1, GBA2, GAA | NOS2 4238/4885NOS3 2590/4885NOS1 4141/4885 |
| US-20260098029-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIFC1 | NOS2 4800/4885NOS3 4461/4885NOS1 4451/4885 |
| US-11236069-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | NOS2 4315/4885NOS3 4245/4885NOS1 3907/4885 |
| US-20220056015-A1 | KIF18A INHIBITORS | KIF18A, KIF18B, KIF15 | NOS2 4275/4885NOS3 4061/4885NOS1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.